@article{TLCR3168,
author = {Yung-Hung Luo and Yuh-Min Chen},
title = {Recent advances in the development of mutant-selective EGFR inhibitors for non-small cell lung cancer patients with EGFR-TKI resistance},
journal = {Translational Lung Cancer Research},
volume = {3},
number = {6},
year = {2014},
keywords = {},
abstract = {Over the last decade, first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) (erlotinib and gefitinib) for the treatment of advanced non-small-cell lung cancer (NSCLC), especially adenocarcinoma, have demonstrated remarkable advances and leaded to improvement in patients’ survival time, either progression-free survival or overall survival. EGFR-TKI therapies also provided a superior quality of life in specific patient populations (1).},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/3168}
}